Acute Myeloid Leukemia (AML) Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at:

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Acute Lymphoblastic Leukemia (ALL) Therapeutics Market Share Assessments for the Regional and Country Level Segments

The global acute lymphoblastic leukemia therapeutics market is expected to witness considerable growth in the coming year since new drug formulations are proving to be the most effective treatment for cancer. An increasing awareness regarding cancer treatment, various technological advancements, high demand for safe and effective medications and high prevalence of cancer, are driving the growth of the global acute lymphoblastic leukemia therapeutics market. The regulatory bodies are also supporting the growth of the global market by providing funding, designations and grants to speed up the drug development process. 

The pipeline of acute lymphoblastic leukemia contains GRASPA (Erythrocytes Encapsulating L-asparaginase), a Phase I drug candidate of ERYtech Pharma, Inc. GRASPA is an encapsulated L-asparaginase product, using the company’s proprietary ERYCAPS platform technology for the treatment of acute lymphoblastic leukemia in adults and children. GRASPA causes systemic degradation of asparagine and inhibits the growth and survival of cancer cells.

Download Report Sample Copy at:   

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids are showing good results for the treatment of acute lymphoblastic leukemia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-lymphoblastic-leukemia-therapeutics-market

Geographically, North America is expected to be the largest market for acute lymphoblastic leukemia, owing to a large number of research and development activities, high healthcare expenditure, and increasing prevalence of cancer. According to National Cancer Institute, estimated new cases of acute lymphoblastic leukemia were 6,590 and estimated deaths were 1,430 in 2016, in the U.S. The U.S. contributed the largest revenue to the North American market in 2016, and it is expected to remain the largest market, globally, during the forecast period.

Some of the key players operating in the global acute lymphoblastic leukemia treatment market are Spectrum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc., ERYtech Pharma, Pfizer, Inc., Amgen, and Takeda Pharmaceutical Company Limited.

Contact:

P&S Intelligence

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Active Pharmaceutical Ingredients Market Opportunity Assessment Study

The global active pharmaceutical ingredient market is growing significantly due to patent expiry of biologic drugs in the industry. Patent expiry of blockbuster drugs has boosted the demand for low cost substitutes, which further increases the demand for active pharmaceutical ingredients in the industry. Moreover, increasing investment into biosimilars is expected to support the growth of the market in the coming years.

  

Massive unexplored market in active pharmaceutical ingredient industry of developing economies are creating ample opportunities for the active pharmaceutical ingredient market to grow at a considerable rate in the coming years. Active pharmaceutical ingredients are the primary components of manufacturing effective and safe essential drugs. The advanced research and development facilities of the companies are supporting to address the demand of the active pharmaceutical ingredient industry.

Download Free Sample of This Research Report: 

Geographically, North America will be leading the global active pharmaceutical ingredient market in the coming years due to increasing research and development programs in the field of drugs and medical science. Asia-Pacific is the fastest growing region in the global active pharmaceutical ingredient market. The major reasons for the fastest growth of the market in the region are increasing healthcare expenditure, large pool of patients, and presence of large pool of generic medicine producers in the region. Moreover, the active pharmaceutical ingredient market is growing due to increasing awareness of lifestyle associated diseses in the emerging countries, such as India and China, of Asia-Pacific region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=active-pharmaceutical-ingredients-market

Some of the companies operating in the active pharmaceutical ingredient market are Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Actavis Plc, Hospira Inc., Boehringer Ingelheim Group, Lonza Group, Cambrex Corporation, Novartis International AG, BASF SE, Pfizer, Inc., Mylan, Inc., Watson Pharmaceutical Inc., and WuXi Apptec.

Read More

Gastrointestinal Over the Counter (OTC) Drugs Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The gastrointestinal over the counter drugs market is growing at a significant rate mainly due to increase in patient population. Strategic alliances are one the major trends that can be seen in the gastrointestinal over the counter drugs market and is supporting the market to grow at a more considerable rate.

Gastrointestinal diseases involve the gastrointestinal tract including stomach, esophagus, large intestine, small intestine, gallbladder, rectum, liver and pancreas. Over the counter (OTC) drugs are medications that are available without any prescription from the doctor. Over the counter drugs are chosen by regulatory agencies very carefully so as to ensure their efficacy and safety.

Request to Get the Sample Pages at: 

The gastrointestinal over the counter drugs can also be bought without any prescription of doctor. The gastrointestinal over the counter drugs are used for indications such as vomiting, gastro esophageal reflux disease (GERD), diarrhea, flatulence and constipation. The over the counter drugs are not compelled by regulatory guidelines, but they need to fulfill the drug monograph of a certain country.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=gastrointestinal-otc-drugs-market

In the U.S., the Food and Drug Administration regulates the manufacturing and sale of over the counter drugs. The Food and Drug Administration compels that all new drugs should obtain a new drug application (NDA) before it enters throughway, but the act excuse any drug which is recognized as effective and safe for the requirement. Some of the over the counter drugs approved in the U.S. are anti-microbial, sunscreens, anti fungal products, and internal and external analgesics. In the U.K., Medicines Regulations 2012 governs the medication. Medication in the country is categorized as a general sales list, prescription only medication and pharmacy medicines.

Some of the competitors in the gastrointestinal over the counter drugs market are Procter & Gamble, GlaxoSmithKline Pharmaceuticals Limited, Purdue Pharma L.P., Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Reckitt Benckiser Group plc, C.B. Fleet Company, Inc., Perrigo Company plc, Sanofi, OMEGA SA, Abbott Laboratories, and Nestle SA.

Read More

Nuclear factor-kappa B Inhibitors Therapeutics Pipeline Analysis, Clinical Trials, Collaboration and Developments

The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development.

Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis/report-sample

According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source.

In May 2014, AnGes MG, Inc. and Shionogi & Co., Ltd. entered in a license agreement to co-develop NF-kB decoy oligodeoxynucleotide for the treatment of atopic dermatitis.

Browse report at: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis

Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Pharma News: Neurofibromatosis Therapeutics Pipeline Review 2018

The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample

Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.

The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) in Phase I study.

Browse report at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Anti-Obesity Drugs Market Analysis by Top Companies, New Technology, Demand and Opportunity

The global anti-obesity drugs market is growing significantly, due to high prevalence of obesity and rich pipeline for anti-obesity drugs. The presence of large patient pool and massive unexplored market in the emerging economies, such as India and China, are creating ample opportunities for the growth of the global anti-obesity drugs market. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost-effective anti-obesity drugs, thus driving the growth of the global anti-obesity drugs market.

Obesity can be defined as a medical condition, in which excessive or abnormal accumulation of fat occurs in a patient. A person with body mass index (BMI) of 30 or above is considered obese. There are several factors causing obesity, such as eating habits, physical inactivity, and genetic makeup. Obesity has serious negative impact on an individual’s health. An obese individual is at a higher risk of developing chronic diseases, such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders. According to the WHO, in 2014, there were 600 million obese people aged 18 years or above, which accounted for 13% of the total adult population in the world. The prevalence of obesity is the highest in the U.S. According to the Center for Disease Control and Prevention (CDC), in the U.S., 35.1% of the adult population aged 20 years or above were obese during 2011 - 2012.

Request to Get the Sample Pages at: 

Geographically, North America leads the global anti-obesity drugs market, due to high incidences of obesity, high healthcare expenditure, and increased awareness about obesity and obesity related risks among patients. In addition, the increasing involvement of government and non-government organizations to educate and aware people about the ill effects of obesity, and extensive research and development activities for the development of anti-obesity drugs are fueling the growth of the anti-obesity drugs market in North America. Asia-Pacific is the fastest growing region in the global anti-obesity drugs market. The fastest growth of the region is attributed to improving healthcare infrastructure, growing healthcare expenditure and increasing geriatric population. Moreover, the anti-obesity drugs market is growing due to increasing research and development facilities, growing disposable income, and presence of large patient pool in the emerging countries, such as India and China.

Some of the major players operating in the global anti-obesity drugs market are F. Hoffmann-La Roche AG, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, and Norgine B.V.

Read More..

Read More